Skip to main content

Advertisement

Table 3 Patient demographics

From: Impact of the stress ulcer prophylactic protocol on reducing the unnecessary administration of stress ulcer medications and gastrointestinal bleeding: a single-center, retrospective pre-post study

 Preintervention, n = 50Postintervention, n = 50p
Age, years, median (IQR)67 (60–75)71 (60–77)0.54
Sex, male, n (%)33 (66)25 (50)0.16
APACHE II score, median (IQR)15 (10–18)17 (10–23)0.16
SOFA score at entry, median (IQR)4 (2–6)5 (2–8)0.46
Glasgow Coma Scale ≤ 10, n (%)6 (12)8 (16)0.77
Length of stay in ICU, days, median (IQR)3 (2–6)3 (2–9)0.41
ICU stay for more than 7 days, n (%)12 (24)17 (34)0.38
30-day mortality, n (%)7 (14)4 (8)0.52
Classification   
 Postoperative, cardiovascular, n (%)2 (4)2 (4)1.00
 Postoperative, others, n (%)32 (64)25 (50)0.23
 Internal, n (%)16 (32)23 (46)0.22
Operation time, min, median (IQR)449 (198–668)435 (165–599)0.59
UGIB history within 1 year, n (%)1 (2)4 (8)0.36
Sepsis, n (%)18 (36)28 (56)0.07
Septic shock, n (%)6 (12)11 (22)0.29
Hepatectomy, n (%)1 (2)3 (6)0.61
Hepatic failure, n (%)1 (2)3 (6)0.61
Multiple trauma, n (%)0 (0)2 (4)0.48
Coagulopathy, n (%)20 (40)29 (58)0.11
Mechanical ventilation, hours, median (IQR)10 (0–59)18 (3–123)0.13
Mechanical ventilation for more than 48 h, n (%)14 (28)19 (38)0.40
Blood purification therapy, n (%)3 (6)9 (18)0.12
Enteral feeding, n (%)17 (34)21 (42)0.54
Steroid, n (%)5 (10)8 (16)0.55
Aspirin, n (%)3 (6)3 (6)1.00
Warfarin, n (%)2 (4)2 (4)1.00
Heparin, n (%)8 (16)14 (28)0.23
Other anticoagulants or antiplatelets, n (%)5 (10)11 (22)0.17
  1. Other anticoagulants or antiplatelet drugs contained low-molecular-weight heparin, danaparoid sodium, nafamostat mesylate, direct thrombin inhibitor, ozagrel sodium, clopidogrel sulfate, and cilostazol
  2. IQR interquartile range, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, UGIB upper gastrointestinal bleeding